Accrued and other liabilities
Breakdown
Segments
Axatilimab - Development ActivitiesView metric
Axatilimab - Commercialization ActivitiesView metric
| Segment | Q4 '25 | Q1 '26 |
|---|---|---|
| Axatilimab - Commercialization Activities | $27.60M | $22.50M |
| Axatilimab - Development Activities | $2.40M | $1.40M |
| Total | $228.07M | $124.92M |